RenovaroCube Appoints New CEO

Renovaro Inc. (NASDAQ: RENB), a leading innovator in cancer diagnostics and therapeutics powered by artificial intelligence, has announced the appointment of Maurice van Tilburg, its Chairman of the Board, as Chief Executive Officer of its subsidiary, GEDi Cube BV—operating as RenovaroCube. GEDi Cube BV is at the forefront of AI-driven cancer diagnostics, integrating multi-omics with liquid biopsies to advance early detection and treatment strategies.

A Leader with Extensive Expertise

Maurice van Tilburg brings a wealth of experience spanning financial services, technology, and innovation. Prior to this role, he served as Director of the Dutch National Growth Fund, overseeing over €11 billion in government investments for technological innovation. His previous positions include CEO of Euronext Amsterdam, where he managed product development, client relationships, and the operational oversight of European stock markets, as well as roles at Techleap.nl supporting the growth of Dutch tech scale-ups.

In addition to his executive roles, Mr. van Tilburg has contributed as an advisor and non-executive board member for multiple startups, further cementing his reputation as a visionary leader.

Driving Innovation at GEDi Cube BV

As CEO of GEDi Cube BV, van Tilburg will focus on commercializing its advanced AI technologies. His efforts will include forging partnerships such as the collaboration with Nebul for early disease detection and advancing the Lumina Project, an innovative platform for Minimal Residual Disease (MRD) detection in lung cancer.

David Weinstein, CEO of Renovaro, expressed confidence in van Tilburg’s leadership:
"Maurice’s expertise in both technology and capital markets will help prioritize the commercialization of our cutting-edge technologies. His leadership will be pivotal in accelerating GEDi Cube’s development pipeline, enabling us to deliver value through a broad range of diagnostic products and services.”

Vision for the Future

Maurice van Tilburg shared his enthusiasm for his new role, stating:
"I am excited to lead GEDi Cube BV into its next phase of growth. The transformative potential of the AI Cube platform can revolutionize cancer diagnostics, from early detection to recurrence risk prediction and beyond. I look forward to collaborating with the GEDi Cube team to harness AI-driven multi-omics biomarkers to transform treatment strategies and improve outcomes for millions worldwide.”

This appointment, unanimously approved by Renovaro’s Board of Directors, marks a significant step in GEDi Cube BV’s journey to revolutionize cancer diagnostics and therapeutics, delivering innovative solutions to improve patient care globally.